secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2022-10-03T23:59:59+00:00
Accession:  0001628280-22-025855
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cardiff Oncology posts updated corporate presentation on onvansertib clinical pipeline
--------------------------------------------------------------------------------

- Presentation covers onvansertib as a PLK1 inhibitor with potential in KRAS-mutated cancers.
- Highlights ongoing Phase 1b/2 trials in mCRC, mPDAC, TNBC, and SCLC with historical ORR benchmarks.
- Includes strategic goals for 2022-2025: demonstration, confirmation, and positioning for registration.
- No specific new clinical data or financial guidance announced in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000162828022025855/0001628280-22-025855-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000162828022025855/crdf-20221003.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-025855

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer